Breaking News Instant updates and real-time market news.

BAC

Bank of America

$29.77

1.235 (4.33%)

, DB

Deutsche Bank

$12.14

0.9 (8.01%)

16:33
07/16/18
07/16
16:33
07/16/18
16:33

Fly Intel: Wall Street's top stories for Monday

Stocks drifted throughout the session as the market appeared to be on hold ahead of the earnings season picking up in earnest this week. The day's economic numbers had little effect on the averages, which moved in a very narrow range. With Netflix (NFLX) set to be the first of the "FANG" pack of tech stocks to report tonight, the market may see some wider in-session swings as the week progresses. ECONOMIC EVENTS: In the U.S., retail sales rose 0.5% in June from the prior month, as expected. The Empire State manufacturing index fell 2.4 points to 22.6, reversing about half of the 4.9 point increase to 25.0 in June. Business inventories rose 04% in May, with sales up 1.4%, as forecast. In China, data was mixed, as a report on Q2 GDP growth was in-line with expectations, June retail sales came in better than expected and June's industrial production fell short of estimates. COMPANY NEWS: Shares of Bank of America (BAC) advanced 4.3% after the bank's headline earnings and revenue topped analysts' consensus forecasts. Additionally, share of Deutsche Bank (DB) trading in New York rose 8% after the German lender announced earlier this morning that it expects to report second quarter results that are "considerably above the average consensus estimate"... FCC Chairman Ajit Pai sunk shares of Tribune Media (TRCO) with his announcement that he has "serious concerns" about the company's proposed deal to be acquired by Sinclair Broadcast Group (SBGI). The FCC has now drafted an order that would designate issues involving certain proposed divestitures for a hearing in front of an administrative law judge, Pai stated. Shares of Tribune fell 16.7% following Pai's announcement, while Sinclair shares declined 11.7%... Bausch Health Companies (BHC), the renamed former Valeant Pharmaceuticals (VRX), began trading under the ticker "BHC" on the New York Stock Exchange and Toronto Stock Exchange today. MAJOR MOVERS: Arconic (ARNC), which rose 10.4% after the Wall Street Journal reported that the company has received interest from private equity firms, including Apollo Global (APO). Also higher was AMD (AMD), which gained 1.9% after Stifel analyst Kevin Cassidy said he believes the chip maker's Zen-based PC CPU lineup "tracked in-line to slightly better than management's guidance." Among the notable losers was OraSure (OSUR), which slipped 5.9% after Stephens analyst Drew Jones downgraded the stock to Equal Weight from Overweight. Also lower was Intellia Therapeutics (NTLA), which fell almost 10% after Nature Biotechnology published a study whose lead author said that the DNA chaos that Crisper brings has been "seriously underestimated," according to STAT. INDEXES: The Dow rose 44.95, or 0.18%, to 25,064.36, the Nasdaq lost 20.26, or 0.26%, to 7,805.72, and the S&P 500 declined 2.88, or 0.1%, to 2,798.43.

BAC

Bank of America

$29.77

1.235 (4.33%)

DB

Deutsche Bank

$12.14

0.9 (8.01%)

TRCO

Tribune Media

$32.05

-6.55 (-16.97%)

SBGI

Sinclair Broadcast

$29.10

-3.9 (-11.82%)

BHC

Bausch Health

$23.01

-0.39 (-1.67%)

VRX

Ticker changed BHC

$0.00

(0.00%)

ARNC

Arconic

$19.19

1.8 (10.35%)

APO

Apollo Global

$35.90

-0.23 (-0.64%)

AMD

AMD

$16.58

0.305 (1.87%)

OSUR

OraSure

$16.28

-1.04 (-6.00%)

NTLA

Intellia Therapeutics

$29.37

-3.23 (-9.91%)

  • 16

    Jul

  • 18

    Jul

  • 02

    Aug

  • 08

    Aug

  • 08

    Aug

  • 27

    Aug

  • 06

    Sep

BAC Bank of America
$29.77

1.235 (4.33%)

02/02/18
MSCO
02/02/18
NO CHANGE
MSCO
BofA, JPMorgan, Citi best positioned for tougher CCAR test, says Morgan Stanley
Morgan Stanley analyst Betsy Graseck said she had expected an easier stress test from the Federal Reserve but that the 2018 CCAR test actually seems tougher than last year, given the more intense recessions and lower asset prices modeled in it. A tougher test makes her less optimistic on her strong payout growth expectations, said Graseck, who sees Bank of America (BAC), JPMorgan (JPM) and Citi (C) as best positioned to "weather the storm" and increase payouts given their resilient balance sheets and significant excess capital. She sees Goldman Sachs (GS), which recently cut buybacks, as at risk from a tougher test, which likely weighs on the bank's 2018 ask, Graseck added.
04/17/18
BMOC
04/17/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America is the best of the 'big four' U.S. banks, says BMO Capital
BMO Capital analyst James Fotheringham kept his Market Perform rating and $34 price target on Bank of America (BAC) after its in-line Q1 earnings but raised his FY18 EPS view to $2.62 from $2.59 and FY19 view to $3.18 from $3.12. Fotheringham says than in contrast, he lowered earnings forecasts for JPMorgan (JPM), Wells Fargo (WFC), and Citigroup (C) because of higher costs and lower revenues, but Bank of America's better than expected net interest income rise justifies his view of the bank as the "best of the bunch". The analyst also notes the bank's more favorable valuation trading at a below-average two-year-forward P/E multiple despite his forecast of double the core earnings growth rate of Bank of America's peers.
04/03/18
BMOC
04/03/18
NO CHANGE
Target $34
BMOC
Market Perform
Bank of America pullback provides a buying opportunity, says BMO Capital
BMO Capital analyst James Fotheringham says that the recent near-10% pullback in the Bank of America stock price provides investors with a buying opportunity. The analyst contends that the bank's stock trades much more closely in line with short term interest rates rather than the 10-year and believes that its net interest margins will prove to be "insensitive" to lower yields on the benchmark as well as higher LIBOR-OIS spreads. Fotheringham keeps his $34 price target and Market Perform rating on Bank of America, adding that its current two-year-forward P/E valuation multiple is close to its long-term historical average.
07/09/18
GSCO
07/09/18
NO CHANGE
GSCO
Bank of America, Morgan Stanley top ideas into Q2 earnings season, says Goldman Sachs
Goldman Sachs analyst Richard Ramsden expects Bank of America (BAC) and Morgan Stanley (MS) to beat consensus estimates in Q2. The analyst argues that both appear best positioned, while he sees risk for U.S. Bancorp (USB) and JPMorgan (JPM). Ramsden highlights Bank of America given the material valuation dislocation that looks to support the stock over time. Additionally, the analyst expects an expense and NII beat for Morgan Stanley.
DB Deutsche Bank
$12.14

0.9 (8.01%)

11/20/17
11/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler sayign valuation following "powerful" share appreciation now reflects the company's progress in growing earnings. 2. Five Below (FIVE) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba citing valuation. 3. Live Nation (LYV) downgraded to In Line from Outperform at Evercore ISI with analyst David Joyce citing valuation. 4. Monster Beverage (MNST) downgraded to Negative from Neutral at Susquehanna with analyst Pablo Zuanic citing its high valuation, which he believes is misplaced due to assumptions about an offer from Coca-Cola (KO). 5. Deutsche Bank (DB) downgraded to Underperform from Market Perform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/01/18
RBCM
06/01/18
DOWNGRADE
RBCM
Underperform
Deutsche Bank downgraded to Underperform from Sector Perform at RBC Capital
02/14/18
02/14/18
DOWNGRADE
Target $48

Hold
Luxoft downgraded to Hold on 'elongated turnaround' at Pivotal Research
As previously reported, Pivotal Research analyst Lou Miscioscia downgraded Luxoft (LXFT) to Hold from Buy, as he now expects most of FY19 to be "a struggle." He had expected the company's two biggest customers - namely Deutsche Bank (DB) and UBS (UBS) - to be about flat for FY19, but now they are suggested to be down 20% and 5%, respectively, Miscioscia said. Noting also that the company cut its FY18 guidance along with its Q3 report, the analyst lowered his price target on Luxoft to $48 from $70.
02/19/18
BOFA
02/19/18
UPGRADE
BOFA
Neutral
Deutsche Bank upgraded to Neutral from Underperform at BofA/Merrill
TRCO Tribune Media
$32.05

-6.55 (-16.97%)

05/07/18
DBAB
05/07/18
UPGRADE
Target $44
DBAB
Buy
Tribune Media upgraded to Buy from Hold at Deutsche Bank
04/25/18
BNCH
04/25/18
NO CHANGE
BNCH
Buy
Sinclair divestiture news a 'much needed' sign of deal progress, says Benchmark
Benchmark analyst Daniel Kurnos said he assumes that Sinclair Broadcast's (SBGI) announcement of its expected station divestitures to satisfy regulatory bodies in the pending Tribune (TRCO) deal is the company's final expected station divestiture list. He doubts Sinclair would publish this list without implicit approval from the DOJ, added Kurnos, calling the announcement a "much needed public sign of progress." Kurnos, who expects Sinclair could generate at least $1.5B-$2B in proceeds, keeps a Buy rating on Sinclair shares.
05/14/18
RBCM
05/14/18
NO CHANGE
Target $38
RBCM
Outperform
Sinclair Broadcast price target lowered to $38 from $46 at RBC Capital
RBC Capital analyst Leo Kulp lowered his price target on Sinclair Broadcast (SBGI) to $38 after its Q1 earnings, saying that its results were similar to peers, but the core advertising trends remain challenging. The analyst also lowers his FY18 EBITDA forecast to $830M from $851M but keeps his Outperform rating, adding that the company generates significant cash flows, which is underappreciated by the market. Kulp further notes that Sinclair Broadcast can take advantage of the increased scale after its Tribune Media (TRCO) acquisition.
05/07/18
DBAB
05/07/18
UPGRADE
Target $44
DBAB
Buy
Tribune Media upgraded to Buy on attractive risk/reward at Deutsche Bank
Deutsche Bank analyst Clay Griffin upgraded Tribune Media (TRCO) to Buy from Hold with an unchanged price target of $44. The analyst sees an attractive event driven risk/reward on the shares. He believes the Sinclair Broadcast (SBGI) merger has a "very high probability" of closing in late Q2, with the shares offering 14% upside based on the implied deal spread. Should the deal break, Griffin sees Tribune Media shares trading down to $28-$31.
SBGI Sinclair Broadcast
$29.10

-3.9 (-11.82%)

04/25/18
04/25/18
UPGRADE
Target $14

Overweight
Tegna upgraded to Overweight on expectations for improved sentiment at Stephens
As previously reported, Stephens analyst Kyle Evans upgraded Tegna (TGNA) to Overweight from Equal Weight, noting that the stock has been under "extreme pressure" since January, which has pushed its valuation to near a 5-year low and roughly in-line with affiliate broadcasting peers Nexstar (NXST), Sinclair Broadcast (SBGI) and Gray Television (GTN). He expects Sinclair's deal with Tribune Media (TRCO) to close in the July/August time frame, which, along with political ad spending should improve investor sentiment in the second half, Evans tells investors. He maintains a $14 price target on Tegna shares.
BHC Bausch Health
$23.01

-0.39 (-1.67%)

VRX Ticker changed BHC
$0.00

(0.00%)

06/29/18
MZHO
06/29/18
NO CHANGE
Target $31
MZHO
Buy
Valeant price target raised to $31 from $27 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Valeant Pharmaceuticals to $31 to reflect higher Xifaxan estimates. The analyst views the Xifaxan franchise, and not Valeant's dermatology portfolio, as the key growth driver for the company. She reiterates a Buy rating on Valeant shares.
07/13/18
EVER
07/13/18
NO CHANGE
EVER
In Line
Evercore says FDA tentatively approves generic of another top 10 Valeant drug
Evercore ISI analyst Umer Raffat notes that the FDA website shows that a generic version of Valeant's (VRX) Apriso, a top 10 product for the company, has been granted a tentative approval. This approval, which was granted to Teva (TEVA), is the second generic approval for one of the company's top 10 products in the last few days, as a generic Uceris approval was also recently granted, added Raffat in his note to investors. He maintains an In Line rating on Valeant shares.
06/27/18
RBCM
06/27/18
NO CHANGE
Target $25
RBCM
Sector Perform
Valeant price target raised to $25 from $19 at RBC Capital
RBC Capital analyst Douglas Miehm raised his price target on Valeant to $25, saying the company's FY18 guidance is likely to prove to be "conservative". The analyst notes the management's commentary that Q1 would mark a trough quarter as its fundamentals are improving, adding that Q2 volumes and price trends for Valeant's largest drug - Xifaxan - point to a strong Q2. Miehm keeps his Sector Perform rating however, citing the likelihood of near-term volatility around the potential delays in its Duobrii psoriasis treatment.
06/28/18
DBAB
06/28/18
NO CHANGE
DBAB
Buy
Deutsche reiterates Buy on Valeant after headquarter visit
Deutsche Bank analyst Gregg Gilbert reiterates a Buy rating on Valeant Pharmaceuticals after visiting the company's headquarters. The analyst left feeling that management is doing the right things to strengthen the business, including investing behind core growth franchises, investing in R&D to support future growth, and strengthening the balance sheet. While keeping his estimates unchanged, Gilbert is more confident in potential drivers of upside, including the growth and durability of the Xifaxan franchise and growth for the Consumer and Bausch and Lomb segments. He continues to like the stock's risk/reward.
ARNC Arconic
$19.19

1.8 (10.35%)

07/16/18
MSCO
07/16/18
NO CHANGE
Target $20
MSCO
Equal Weight
Morgan Stanley says Arconic LBO could work, but execution matters in near-term
After The Wall Street Journal reported that Arconic has received "expressions of interest" from a number of private-equity firms, Morgan Stanley analyst Rajeev Lalwani said two things stand out to make Arconic a plausible LBO candidate: its low EV/EBITDA multiple and its a cash flow profile, which has room for improvement. While the reported private equity interest "adds a level of intrigue," Lalwani still believes headwinds within it rings and disks business, working capital and capex issues and volatility associated with aluminum prices will be the key driver of shares in the near-term. Given the aforementioned execution concerns, Lalwani keeps an Equal Weight rating and $20 price target on Arconic shares, which are up 12% to $19.53 in pre-market trading.
07/16/18
JEFF
07/16/18
INITIATION
Target $23
JEFF
Buy
Arconic initiated with a Buy at Jefferies
Jefferies analyst Martin Englert started Arconic with a Buy rating and $23 price target. The company's "depressed" share price "creates a window of optionality" for management to utilize its $500M buyback and the recent reported interest from private equity is likely supportive of the valuation, Englert tells investors in a research note.
07/16/18
FBCO
07/16/18
NO CHANGE
Target $28
FBCO
Outperform
Arconic could be worth $24-$26 per share in buyout, says Credit Suisse
Credit Suisse analyst Curt Woodworth views Arconic (ARNC) as a "very viable" leveraged buyout candidate given its "highly depressed" multiples, operational and financial mismanagement, and "very strong" positions in automotive and aerospace end markets. The analyst believes the company could be worth $24-$26 per share in a buyout. The stock in morning trading is up 9%, or $1.60, to $18.98 after the Wall Street Journal reported that Arconic is the subject of takeover interest from private equity firms including Apollo Global Management (APO). Woodworth has an Outperform rating on the shares with a $28 price target.
05/31/18
ARGS
05/31/18
DOWNGRADE
ARGS
Hold
Arconic downgraded to Hold from Buy at Argus
Argus analyst John Eade downgraded Arconic to Hold from Buy, telling investors in a research note that shares have underperformed the market over the past quarter and its share price has been volatile over the last year, rising on expectations for infrastructure spending under the Trump administration and then falling on concerns about the role of its products in the fatal Grenfell Tower fire. The analyst says he may look to get Arconic shares back to a Buy rating once margins show signs of stabilizing.
APO Apollo Global
$35.90

-0.23 (-0.64%)

07/13/18
WELS
07/13/18
NO CHANGE
Target $95
WELS
Outperform
Nexstar 'both a buyer and a seller,' says Wells Fargo
After hosting a road show with Nexstar (NXST) CFO Tom Carter, Wells Fargo analyst Marci Ryvicker noted that there was no comment on the recent report on interest from Apollo (APO), with Carter quoted as saying the company would "not comment on rumor or speculation." Ryvicker adds that her opinion is that Reuters picked up some "old news" that investors would like to resurrect. However, the analyst also noted that Carter was clear that Nexstar is both a buyer and a seller for the right price. Ryvicker, who also noted the CFO said "business is just fine," keeps an Outperform rating on Nexstar shares and raised her price target on the stock to $95 from $92.
06/29/18
WELS
06/29/18
NO CHANGE
Target $38
WELS
Outperform
Apollo Global shares not fully appreciating catalysts, says Wells Fargo
After hosting investor meetings with management, Wells Fargo analyst Christopher Harris says Apollo Global has catalysts that have the potential to drive growth and possible valuation expansion. These include a ramp-up in insurance affiliates and fee earnings, the monetization of PE Fund 8 and the potential for a c-corp conversion, Harris tells investors in a research note. The analyst believes these catalysts are not fully appreciated in shares of Apollo Global. He keeps an Outperform rating on the name with a $38 price target.
07/12/18
RBCM
07/12/18
NO CHANGE
Target $90
RBCM
Outperform
PE interest in Nexstar reinforces positive view on its FCF, says RBC Capital
RBC Capital analyst Leo Kulp kept his Outperform rating and $90 price target on Nexstar (NXST), saying yesterday's reports of a potential interest in the company from Apollo Global (APO) reinforces the positive view among investors regarding its free cash flow prospects. The analyst adds that he has previously made the case for the company's free cash flow being "much more durable" than believed. Kulp also estimates that a private equity buyer could pay over $95 per share for Nexstar.
AMD AMD
$16.58

0.305 (1.87%)

07/13/18
BFIN
07/13/18
NO CHANGE
BFIN
BlueFin says crypto weakness not the only issue for GPU makers
Following an Asian trip to check on semiconductor markets, BlueFin analyst Paul Peterson said his current reads indicate that cryptocurrency market demand remains weak, but this is "not the only thing plaguing the graphics card market." Gamer demand also appears relatively muted, said Peterson, who tells investors in his note that checks indicate GPU card sales dropped by more than 50% in the North America and Europe retail channels. The analyst, who has heard that Nvidia (NVDA) is pressuring retailers to drop their prices, said his work shows graphics card prices have dropped sharply. However, while crypto demand is still weak and overall graphics card sales are sluggish, he thinks data center momentum will be the primary driver for AMD (AMD) and Nvidia stocks in the near-term. Shares of Nvidia are down about 1% to $248.92 in early trading, while AMD has also declined about 1%.
07/05/18
KEYB
07/05/18
NO CHANGE
Target $60
KEYB
Overweight
Intel price target lowered to $60 from $65 at KeyBanc
KeyBanc analyst Michael McConnell lowered his price target for Intel (INTC) to $60 from $65 saying that while DCG demand trends remain robust in the near-term, he believes that 14nm notebook platform delays in 2H18, a sub-seasonal Q3 demand outlook at notebook ODMs, new AMD (AMD) EPYC design wins at cloud customers for 2019, and 10nm manufacturing delays will likely lead to a lower multiple for the stock. McConnell reiterates an Overweight rating on Intel's shares.
06/26/18
06/26/18
INITIATION

Hold
AMD initiated with a Hold at Benchmark
As previously reported, Benchmark analyst Mike Burton initiated AMD (AMD) with a Hold rating. While investors are particularly positive on its relatively new EPYC CPU server offering given recent commentary from Intel (INTC) that it expects AMD to take increasing share of the server market, the stock's valuation gives him pause.
06/26/18
BOFA
06/26/18
NO CHANGE
BOFA
Data on world's top supercomputers positive for Nvidia, says BofA/Merrill
BofA Merrill Lynch analyst Vivek Arya said new data on the world's top supercomputers is positive for Nvidia (NVDA), noting that accelerator adoption grew 21% year-over-year and Nvidia's share jumped 800 bps year-over-year to 89%. Supercomputing is quickly becoming a critical national resource, which is very positive for the "arms-dealers" like Nvidia, AMD (AMD), Intel (INTC) and Cavium (CAVM), which is being bought by Marvell (MRVL), added Arya.
OSUR OraSure
$16.28

-1.04 (-6.00%)

07/16/18
SPHN
07/16/18
DOWNGRADE
SPHN
Equal Weight
OraSure downgraded to Equal Weight from Overweight at Stephens
07/16/18
07/16/18
DOWNGRADE
Target $19

Equal Weight
OraSure downgraded to Equal Weight with unchanged $19 target at Stephens
As previously reported, Stephens analyst Drew Jones downgraded OraSure to Equal Weight from Overweight, as he feels the "valuable" molecular collection business and long-term prospects for microbiome are largely reflected in the stock at its current levels. While he finds the company's ongoing strategic review "intriguing," Jones does not believe it can be presented in a way to serve as a meaningful near-term catalyst for the stock, he added. Jones maintains a $19 price target on OraSure shares.
05/04/18
ADAM
05/04/18
NO CHANGE
Target $20
ADAM
Buy
OraSure selloff looks overdone, says Canaccord
Canaccord analyst Mark Massaro noted OraSure shares traded down following its Q1 beat. The analyst thinks the weakness is overblown as he notes molecular collections grew revenues 72% year-over-year and continues to win new business in a huge market. He also noted the leadership changes and the ongoing strategic review. Massaro maintained his Buy rating and lowered his price target to $20 from $24 on OraSure shares.
11/22/17
JEFF
11/22/17
NO CHANGE
JEFF
Hold
Jefferies unclear how much of 'eye-catching' OraSure contract is incremental
Jefferies analyst Brandon Couillard said the size of the $143M contract announced by OraSure was "eye-catching," but that it is still unclear how much of this is truly incremental to the current run-rate with the customer in question. The analyst, who said his "best guess" and current assumption is that the contract is with 23&Me, maintains a Hold rating on OraSure shares.
NTLA Intellia Therapeutics
$29.37

-3.23 (-9.91%)

05/15/18
CHDN
05/15/18
UPGRADE
CHDN
Buy
Intellia Therapeutics upgraded to Buy from Neutral at Chardan
06/11/18
MSCO
06/11/18
NO CHANGE
MSCO
Equal Weight
Editas CRISPR-related cancer risks seem overblown, says Morgan Stanley
After studies published in Nature Medicine by Novartis (NVS) and the Karolinska Institute suggested an increased risk of cancer that could result from editing genomes with CRISPR-Cas9, Morgan Stanley analyst Matthew Harrison said the concerns are theoretical and noted that STAT's article on the subject does not provide any link to an increased risk for CRISPR activation of p53 versus natural activation when DNA breaks. Harrison thinks theoretical concerns will continue to arise regarding gene editing until the first substantial set of clinical data is generated, but he does not see any direct concerns for Editas Medicine (EDIT) and expects the stock to recover in the coming days. He keeps an Equal Weight rating and $39 price target on Editas shares. Morgan Stanley does not cover Intellia Therapeutics (NTLA) or Crispr Therapeutics (CRSP), which have also seen weakness following the Nature Medicine publications.
03/08/18
JMPS
03/08/18
INITIATION
Target $76
JMPS
Outperform
Intellia Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Michael King started Intellia Therapeutics with an Outperform rating and $76 price target, stating that the company is leading competitors in the gene-editing space in its efforts to develop in vivo gene-editing approaches and that its partnerships validate its in vivo LNP approach.
03/07/18
LEHM
03/07/18
NO CHANGE
Target $46
LEHM
Overweight
Intellia Therapeutics price target raised to $46 from $33 at Barclays
Barclays analyst Gena Wang raised her price target for Intellia Therapeutics (NTLA) to $46 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Intellia shares and keeps an Overweight rating on the name.

TODAY'S FREE FLY STORIES

10:30
08/16/18
08/16
10:30
08/16/18
10:30
General news
EIA natural gas storage change for week ending August 10 »

Gas inventories 33 Bcf…

CTL

CenturyLink

$22.96

0.48 (2.14%)

10:30
08/16/18
08/16
10:30
08/16/18
10:30
Options
Sweep buyer of CenturyLink in the money puts as shares reach 52-week highs »

Sweep buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBNY

Signature Bank

$114.29

1.53 (1.36%)

10:29
08/16/18
08/16
10:29
08/16/18
10:29
Hot Stocks
Signature Bank announces special meeting to approve stock buyback program »

Signature Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 29

    Oct

10:20
08/16/18
08/16
10:20
08/16/18
10:20
General news
Market opens sharply higher on renewed trade hopes »

Stock futures were…

ROK

Rockwell Automation

$172.79

1.13 (0.66%)

10:20
08/16/18
08/16
10:20
08/16/18
10:20
Options
Call buyer in Rockwell as shares see strength »

Call buyer in Rockwell as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
08/16/18
08/16
10:17
08/16/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$122.72

0.03 (0.02%)

10:16
08/16/18
08/16
10:16
08/16/18
10:16
Hot Stocks
KFx Medical, Zimmer Biomet enter into license agreement »

KFx Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
08/16/18
08/16
10:16
08/16/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
08/16/18
08/16
10:15
08/16/18
10:15
General news
Breaking General news story  »

Week of 8/10 EIA Natural…

POST

Post Holdings

$96.51

1.73 (1.83%)

, SYK

Stryker

$168.57

1.735 (1.04%)

10:12
08/16/18
08/16
10:12
08/16/18
10:12
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

POST

Post Holdings

$96.51

1.73 (1.83%)

SYK

Stryker

$168.57

1.735 (1.04%)

AVEO

Aveo Pharmaceuticals

$2.26

0.085 (3.91%)

UXIN

Uxin

$5.58

0.315 (5.98%)

ACRX

AcelRx

$2.95

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

  • 23

    Aug

  • 04

    Sep

  • 12

    Sep

AZN

AstraZeneca

$38.35

-0.1 (-0.26%)

, CX

Cemex

$6.80

0.005 (0.07%)

10:12
08/16/18
08/16
10:12
08/16/18
10:12
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

AZN

AstraZeneca

$38.35

-0.1 (-0.26%)

CX

Cemex

$6.80

0.005 (0.07%)

CVE

Cenovus Energy

$8.97

0.015 (0.17%)

NANO

Nanometrics

$41.46

-3.74 (-8.27%)

COTY

Coty

$11.37

-0.06 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 21

    Aug

  • 25

    Aug

  • 28

    Aug

  • 09

    Oct

LULU

Lululemon

$127.75

1.27 (1.00%)

, KMB

Kimberly-Clark

$117.47

1 (0.86%)

10:12
08/16/18
08/16
10:12
08/16/18
10:12
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

LULU

Lululemon

$127.75

1.27 (1.00%)

KMB

Kimberly-Clark

$117.47

1 (0.86%)

ERJ

Embraer

$19.49

0.855 (4.59%)

FTI

TechnipFMC

$28.19

0.59 (2.14%)

AVLR

Avalara

$37.90

3.22 (9.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 30

    Aug

  • 12

    Sep

RADA

RADA Electronic

$2.55

0.01 (0.39%)

10:10
08/16/18
08/16
10:10
08/16/18
10:10
Initiation
RADA Electronic initiated  »

RADA Electronic initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$43.82

0.35 (0.81%)

10:10
08/16/18
08/16
10:10
08/16/18
10:10
Options
Another utility name with one day call buying »

Another utility name with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LULU

Lululemon

$127.16

0.68 (0.54%)

, KMB

Kimberly-Clark

$117.91

1.44 (1.24%)

10:06
08/16/18
08/16
10:06
08/16/18
10:06
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

LULU

Lululemon

$127.16

0.68 (0.54%)

KMB

Kimberly-Clark

$117.91

1.44 (1.24%)

COTY

Coty

$11.34

-0.09 (-0.79%)

ATVI

Activision Blizzard

$69.47

0.2 (0.29%)

NKE

Nike

$80.12

0.56 (0.70%)

UA

Under Armour

$19.22

0.19 (1.00%)

UAA

Under Armour

$20.79

0.2 (0.97%)

VFC

VF Corp.

$92.13

-0.17 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 30

    Aug

  • 04

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

C

Citi

$69.49

0.85 (1.24%)

, CAT

Caterpillar

$134.50

2.49 (1.89%)

10:03
08/16/18
08/16
10:03
08/16/18
10:03
Hot Stocks
Citi Retail Services announces long-term agreement with Caterpillar Financial »

Citi Retail Services (C)…

C

Citi

$69.49

0.85 (1.24%)

CAT

Caterpillar

$134.50

2.49 (1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

GTN

Gray Television

$16.40

-0.05 (-0.30%)

, CBS

CBS

$52.89

0.09 (0.17%)

10:02
08/16/18
08/16
10:02
08/16/18
10:02
Hot Stocks
Gray Television to sell WSWG-TV in Albany, Georgia »

Gray Television (GTN)…

GTN

Gray Television

$16.40

-0.05 (-0.30%)

CBS

CBS

$52.89

0.09 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 27

    Sep

GM

General Motors

$36.49

0.55 (1.53%)

, RDS.A

Royal Dutch Shell

$63.18

0.95 (1.53%)

10:02
08/16/18
08/16
10:02
08/16/18
10:02
Hot Stocks
GM, Shell deliver nationwide in-dash fuel payment »

Shell Oil Company (RDS.A)…

GM

General Motors

$36.49

0.55 (1.53%)

RDS.A

Royal Dutch Shell

$63.18

0.95 (1.53%)

RDS.B

Royal Dutch Shell

$65.20

0.92 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Aug

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$9.12

-0.63 (-6.46%)

10:00
08/16/18
08/16
10:00
08/16/18
10:00
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF falls -6.6% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNL

Global Net Lease

$20.61

-1.47 (-6.66%)

10:00
08/16/18
08/16
10:00
08/16/18
10:00
Hot Stocks
Global Net Lease falls -6.6% »

Global Net Lease is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

DDS

Dillard's

$74.93

-8.05 (-9.70%)

10:00
08/16/18
08/16
10:00
08/16/18
10:00
Hot Stocks
Dillard's falls -9.8% »

Dillard's is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATV

Acorn International

$17.84

(0.00%)

10:00
08/16/18
08/16
10:00
08/16/18
10:00
Hot Stocks
Acorn International rises 10.1% »

Acorn International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$128.36

0.3 (0.23%)

10:00
08/16/18
08/16
10:00
08/16/18
10:00
Options
Electronic Arts with repeat option action late yesterday »

Electronic Arts with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

WUBA

58.com

$65.22

6.63 (11.32%)

10:00
08/16/18
08/16
10:00
08/16/18
10:00
Hot Stocks
58.com rises 11.2% »

58.com is up 11.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

BGG

Briggs & Stratton

$20.54

2.13 (11.57%)

10:00
08/16/18
08/16
10:00
08/16/18
10:00
Hot Stocks
Briggs & Stratton rises 11.7% »

Briggs & Stratton is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.